Figure 3.

Comparison of NanoVelcro and CellSearch^TM Assays in CTC enumeration for metastatic castration-resistant prostate cancer (mCRPC) patients. More than 100 contemporary CTC enumeration results from NanoVelcro and CellSearch^TM Assays are shown in (a). The data demonstrated parallels and differences in the output of these two assays. The NanoVelcro CTC assay detected counts ranging from 0-98 cells per 7.5 mL of blood, in comparison to CellSearch^TM that yielded 0-905 counts per 7.5 mL of blood. (b) A typical case showing the NanoVelcro and CellSearch^TM counts in reflection of patient's disease progression. Cell counts decreased immediately after the initiation of anti-cancer therapies, and rose at the time of disease progression. (c) (Upper row) some of cells present with strong CK fluorescence signal and weak CD45 signal (arrowheads), but could be identified as WBCs with fluorescence staining neutrophil markers (lower row), suggesting the existence of false positive events that may contribute to the unusually high cell counts.